NanoViricides Inc (NYSEMKT:NNVC) shares fell 2.61% to $1.12 and were flat in after-hours trading. Share prices have been trading in a 52-week range of $1.03 to $2.08. The company has a market cap of $72.89 million at 62.82 million shares outstanding.
NanoViricides Inc announced that Eugene Seymour, MD, MPH, CEO, will present information about the Company and its progress towards human trials at the Planet Microcap conference at the Planet Hollywood Hotel on April 27, 12:30 pm. This conference brings together the most promising companies and the top dealmakers in MicroCap Finance for three days of company presentations, one-on-one meetings, and networking.
The company has previously reported that its broad spectrum anti-herpesvirus drug candidates were highly effective in treating HSV-1 infection in a lethal animal model. Among its candidates, NanoViricides Inc believes that its drug candidate for the topical treatment of shingles would have the fastest drug development path towards human clinical trials. With that, it is working on pre-clinical development of this drug candidate and is exploring further clinical development path for the resulting drug candidate.
Apart from that, the company has also been working on scaling up production of this drug candidate with the goal of developing 500g to 1kg per batch production capability. It is urrently performing the Chemistry, Manufacture and Controls studies needed for filing an Investigational Drug Application for the shingles drug candidate with the US FDA.
NanoViricides Inc is a development-stage nano-biopharmaceutical company with several drugs in various stages of development. It focuses on its research and clinical programs on specific anti-viral therapeutics and is engaged in the application of nanomedicine technologies to the issues of viral diseases.
The company’s nanoviricide technology enables direct attacks at multiple points on a virus particle. In addition, the nanoviricide technology also simultaneously enables attacking the intracellular reproduction of the virus by incorporating one or more active pharmaceutical ingredients within the core of the nanoviricide. The nanoviricide technology is engaged in both attacking extracellular virus thereby breaking the reinfection cycle, and simultaneously disrupting intracellular production of the virus, thereby enabling complete control of a virus infection.